Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | YARS1 | P54577 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30839485 | 1.00 | OPRD1 (0.64) | OPRD1OPRM1SLC6A2OPRK1SLC7A5 | |
| SCHEMBL30811089 | 0.96 | OPRD1 (0.63) | OPRD1OPRM1SLC6A2OPRK1 | |
| SCHEMBL31257017 | 0.95 | SLC6A2 (0.59) | OPRD1OPRM1SLC6A2OPRK1NPY1R | |
| SCHEMBL29823718 | 0.94 | OPRD1 (0.70) | OPRD1OPRM1SLC6A2OPRK1 | |
| SCHEMBL30565312 | 0.92 | OPRD1 (0.59) | OPRD1OPRM1SLC6A2OPRK1 | |
| SCHEMBL29987086 | 0.92 | OPRM1 (0.56) | OPRD1OPRM1SLC6A2OPRK1NPY1R | |
| SCHEMBL9822736 | 0.92 | SLC7A5 (0.58) | OPRD1OPRM1OPRK1SLC7A5YARS1 | |
| SCHEMBL8529219 | 0.92 | SLC7A5 (0.58) | OPRD1OPRM1OPRK1SLC7A5YARS1 | |
| SCHEMBL8529222 | 0.92 | SLC7A5 (0.58) | OPRD1OPRM1OPRK1SLC7A5YARS1 | |
| SCHEMBL30309232 | 0.92 | SLC7A5 (0.58) | OPRD1OPRM1OPRK1SLC7A5YARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083949-A1 | CELL PENETRATING PEPTIDE COMPOSITIONS AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-03-14 | — | — | US | claimed |
| US-20240083949-A1 | CELL PENETRATING PEPTIDE COMPOSITIONS AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083949-A1 | CELL PENETRATING PEPTIDE COMPOSITIONS AND METHODS THEREOF | VIP, IAPP, ANXA5 | OPRD1 4341/4885OPRM1 4159/4885SLC6A2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.